Number of the records: 1  

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

  1. 1.
    0566813 - MBÚ 2023 RIV CH eng J - Journal Article
    Reiss, Zuzana - Rob, F. - Kolář, M. - Schierová, Dagmar - Kreisinger, J. - Jacková, Zuzana - Roubalová, Radka - Coufal, Štěpán - Mihula, Martin - Thon, Tomáš - Bajer, Lukáš - Nováková, M. - Vašátko, M. - Kostovčíková, Klára - Galanová, Natálie - Lukáš, M. - Kverka, Miloslav - Třešňák Hercogová, J. - Tlaskalová-Hogenová, Helena - Jirásková Zákostelská, Zuzana
    Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy.
    Frontiers in Cellular and Infection Microbiology. Roč. 13, January 10 (2023), č. článku 1064537. ISSN 2235-2988. E-ISSN 2235-2988
    R&D Projects: GA MZd(CZ) NV18-09-00493; GA MZd(CZ) NU22J-05-00056; GA ČR(CZ) GA20-03997S
    Institutional support: RVO:61388971
    Keywords : Skin microbiota * IBD * 16S RNA sequencing * Serum biomarker * TNF-alpha antagonist * Skin adverse events
    OECD category: Microbiology
    Impact factor: 5.7, year: 2022
    Method of publishing: Open access
    https://www.frontiersin.org/articles/10.3389/fcimb.2022.1064537/full

    Crohn’s disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well recognized. Inhibitors of TNF have been successful in IBD treatment, but up to a quarter of patients suffer from unpredictable skin adverse events (SkAE). For this purpose, we analyzed temporal dynamics of skin microbiota and serum
    markers of inflammation and epithelial barrier integrity during anti-TNF therapy and SkAE manifestation in IBD patients. We observed that the skin microbiota signature of IBD patients differs markedly from healthy subjects. In particular, the skin microbiota of CD patients differs significantly from that of UC patients and healthy subjects, mainly in the retroauricular crease. In addition, we showed that anti-TNF-related SkAE are associated with specific shifts in skin microbiota profile and with a decrease in serum levels of L-FABP and I-FABP in
    IBD patients. For the first time, we showed that shifts in microbial composition in IBD patients are not limited to the gut and that skin microbiota and serum markers of the epithelium barrier may be suitable markers of SkAE during anti-TNF therapy.

    Permanent Link: https://hdl.handle.net/11104/0338102

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.